Development of Polygenic Risk Scores for Diabetes and Complications across the Life-Span in Populations of Diverse Ancestry
不同血统人群终生糖尿病和并发症的多基因风险评分的制定
基本信息
- 批准号:10212697
- 负责人:
- 金额:$ 98.69万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-06-08 至 2026-03-31
- 项目状态:未结题
- 来源:
- 关键词:AccountingAddressBayesian MethodBiological ProcessCollectionComplexComplications of Diabetes MellitusCoupledDataDevelopmentDiabetes MellitusDiabetic NephropathyDiabetic RetinopathyDiseaseDisease modelElectronic Health RecordEthnic groupEuropeanGeneticGenomicsGenotypeGestational DiabetesGoalsHealthHealthcare SystemsIndividualInformaticsInsulin-Dependent Diabetes MellitusLife Cycle StagesLinkage DisequilibriumLongevityMethodsNon-Insulin-Dependent Diabetes MellitusOutcomePatient CarePerformancePhenotypePopulationPopulation HeterogeneityPrevention strategyProcessRaceResearchRisk FactorsSampling StudiesScoring MethodSecureSocietiesSystemTestingTrainingVariantVisualizationWeightWorkbiobankclinical riskcohortdata harmonizationdata sharingdiabetes riskdisorder riskdiverse dataethnic diversitygenetic approachgenetic risk factorgenetic variantgenome wide association studygenome-widegenomic dataglobal healthhealth disparityimprovedlarge datasetsmethod developmentmultidisciplinarynovelpersonalized carephenotypic datapolygenic risk scoreprecision medicineracial and ethnic disparitiesrisk predictionsocioeconomic disparitystatisticstooltrait
项目摘要
Abstract
Large-scale genome wide association studies (GWAS) have identified a large number of genetic variants
associated with complex diseases. The aggregation of all the variants that are known to contribute to the disease
in the form of polygenic risk scores (PRS) improves the prediction of a range of complex diseases. Most PRS
have been developed within European ancestry study samples and have shown to perform poorly in other
race/ethnic groups, further exaggerating health disparities across ancestries. As genetic approaches for
precision medicine become more popular, there is a critical need to responsively and pro-actively expand access
to accurate PRS. Specifically, diabetes, and its associated complications are one of the biggest global health
problems of the 21st century. In fact, type 1 and type 2 diabetes (T1D and T2D), gestational diabetes (GDM) and
related complications are excellent disease models to study the utility of PRS for predicting heterogenous and
complex health outcomes in a setting where dramatic racial/ethnic and socioeconomic disparities exist. Not only
are PRS useful to predict T1D and T2D, but they can distinguish between T1D and T2D, and between T2D
subtypes. The wealth of existing trans-ancestry GWAS data from diabetes subtypes, complications, and
quantitative traits recently generated provides a unique opportunity for constructing highly transferable PRS
across populations. To address the disparities in PRS across ancestries, we have assembled a multi-disciplinary
team to aggregate and analyze the largest existing genetic data from more than 1.8 M individuals (35% non-
European) with T1D, T2D, GDM and glycemia-related complications and quantitative traits to improve the PRS
prediction of diabetes and progression across lifespan in diverse ancestries with these Aims: (1) Collection,
harmonization and integration of large-scale, multi-ancestry cohorts with diabetes traits across the life-span and
genomics for development, training and testing PRS for diverse ancestries; (2) Development of methods to
improve PRS prediction in non-European populations by using Bayesian approaches that allow integration of
linkage disequilibrium and summary statistics from several ancestries. (3) Development, testing, and comparing
performance of PRS for each trait, development of risk prediction tools that integrate clinical and genetic risk
factors, and assessment of scenarios where PRS improve the prediction. Accomplishing the aims of this proposal
will demonstrate how genomic data can inform more efficient and targeted preventive strategies within healthcare
systems and across ethnically diverse populations. Findings are expected to advance precision care of patients
with diabetes and related conditions in people of diverse ancestral background and serve as a paradigm for
many other complex diseases.
摘要
大规模的全基因组关联研究(GWAS)已经确定了大量的遗传变异
与复杂疾病有关。所有已知导致疾病的变异的聚集
以多基因风险评分(PRS)的形式改进了对一系列复杂疾病的预测。大多数PRS
已经在欧洲血统研究样本中开发,并且在其他研究中表现不佳。
种族/族裔群体,进一步扩大了各祖先之间的健康差距。作为遗传方法,
精准医疗越来越受欢迎,迫切需要响应和积极主动地扩大获取
准确的PRS。具体来说,糖尿病及其相关并发症是全球最大的健康问题之一,
21世纪世纪的问题事实上,1型和2型糖尿病(T1 D和T2 D),妊娠糖尿病(GDM)和
相关并发症是研究PRS预测异质性和
在种族/族裔和社会经济存在巨大差异的环境中,不仅
PRS对预测T1 D和T2 D有用吗?但它们可以区分T1 D和T2 D以及T2 D
亚型从糖尿病亚型、并发症和
最近产生的数量性状为构建高度可转移的PRS提供了独特的机会
在人群中。为了解决不同祖先在减贫战略方面的差异,我们组织了一个多学科的
团队聚集和分析来自超过180万个体的最大现有遗传数据(35%非
欧洲)与T1 D、T2 D、GDM和糖尿病相关并发症和数量性状,以改善PRS
预测不同祖先的糖尿病及其在整个生命周期中的进展,目标如下:(1)收集,
协调和整合具有糖尿病特征的大规模、多祖先队列,
基因组学促进发展,培训和测试不同祖先的PRS;(2)开发方法,
通过使用贝叶斯方法改进非欧洲人群的PRS预测,
连锁不平衡和几个祖先的汇总统计。(3)开发、测试和比较
对每个特征进行PRS,开发整合临床和遗传风险的风险预测工具
因素,并评估减贫战略改进预测的情景。实现本提案的目标
将展示基因组数据如何为医疗保健提供更有效和更有针对性的预防策略
系统和不同种族的人口。研究结果有望推动患者的精确护理
糖尿病和相关疾病的人不同的祖先背景,并作为一个范例,
许多其他复杂的疾病。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Alisa Knodle Manning其他文献
Alisa Knodle Manning的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Alisa Knodle Manning', 18)}}的其他基金
Development of Polygenic Risk Scores for Diabetes and Complications across the Life-Span in Populations of Diverse Ancestry
不同血统人群终生糖尿病和并发症的多基因风险评分的制定
- 批准号:
10612985 - 财政年份:2021
- 资助金额:
$ 98.69万 - 项目类别:
Development of Polygenic Risk Scores for Diabetes and Complications across the Life-Span in Populations of Diverse Ancestry
不同血统人群终生糖尿病和并发症的多基因风险评分的制定
- 批准号:
10424449 - 财政年份:2021
- 资助金额:
$ 98.69万 - 项目类别:
Integrating diabetes pathophysiology from genotype to phenotype in whole genome sequence association studies of glycemic traits
将糖尿病病理生理学从基因型到表型整合到血糖特征的全基因组序列关联研究中
- 批准号:
9014210 - 财政年份:2015
- 资助金额:
$ 98.69万 - 项目类别:
TOPMed Omics of Type 2 Diabetes and Quantitative Traits
2 型糖尿病的 TOPMed 组学和定量特征
- 批准号:
10533311 - 财政年份:2008
- 资助金额:
$ 98.69万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 98.69万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 98.69万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 98.69万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 98.69万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 98.69万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 98.69万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 98.69万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 98.69万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 98.69万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 98.69万 - 项目类别:
Research Grant